DK2356101T3 - Pyrimidin- og triazin-sulfonamidderivater som bradykinin B1-receptor (B1R)-inhibitorer til behandling af smerte. - Google Patents
Pyrimidin- og triazin-sulfonamidderivater som bradykinin B1-receptor (B1R)-inhibitorer til behandling af smerte.Info
- Publication number
- DK2356101T3 DK2356101T3 DK09740860.3T DK09740860T DK2356101T3 DK 2356101 T3 DK2356101 T3 DK 2356101T3 DK 09740860 T DK09740860 T DK 09740860T DK 2356101 T3 DK2356101 T3 DK 2356101T3
- Authority
- DK
- Denmark
- Prior art keywords
- bradykinin
- triazine
- pyrimidine
- pain
- inhibitors
- Prior art date
Links
- 102000017916 BDKRB1 Human genes 0.000 title 1
- 108010044231 Bradykinin B1 Receptor Proteins 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- CYIBYUPNLHCRPV-UHFFFAOYSA-N triazine-4-sulfonamide Chemical class NS(=O)(=O)C1=CC=NN=N1 CYIBYUPNLHCRPV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08018514 | 2008-10-23 | ||
| PCT/EP2009/007568 WO2010046109A1 (de) | 2008-10-23 | 2009-10-22 | Pyrimidin- und triazin- sulfonamidderivate als bradykinin b1 rezeptor (b1r) inhibitoren zur behandlung von schmerz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2356101T3 true DK2356101T3 (da) | 2013-05-27 |
Family
ID=40386034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09740860.3T DK2356101T3 (da) | 2008-10-23 | 2009-10-22 | Pyrimidin- og triazin-sulfonamidderivater som bradykinin B1-receptor (B1R)-inhibitorer til behandling af smerte. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8269000B2 (da) |
| EP (1) | EP2356101B1 (da) |
| JP (1) | JP2012506396A (da) |
| AR (1) | AR073919A1 (da) |
| AU (1) | AU2009306723A1 (da) |
| BR (1) | BRPI0920496A2 (da) |
| CA (1) | CA2741349A1 (da) |
| CY (1) | CY1113942T1 (da) |
| DK (1) | DK2356101T3 (da) |
| ES (1) | ES2409109T3 (da) |
| HR (1) | HRP20130423T1 (da) |
| MX (1) | MX2011004211A (da) |
| PL (1) | PL2356101T3 (da) |
| PT (1) | PT2356101E (da) |
| SI (1) | SI2356101T1 (da) |
| TW (1) | TW201022267A (da) |
| WO (1) | WO2010046109A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011078143A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| EP2825694A4 (en) * | 2012-03-16 | 2016-04-20 | Impossible Foods Inc | AFFINITY REAGENTS FOR PROTEIN CLEANING |
| US20160068486A1 (en) * | 2013-04-22 | 2016-03-10 | Reuter Chemische Apparatebau Kg | Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| CN109265395B (zh) * | 2018-09-21 | 2021-10-26 | 中国烟草总公司郑州烟草研究院 | 一种二氯喹啉酸半抗原与抗原的制备方法及应用 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE250053T1 (de) * | 1999-07-15 | 2003-10-15 | Pharmacopeia Inc | Bradikinin b1 rezeptor antagonisten |
| WO2007101007A2 (en) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Aryl sulfonyl heterocycles |
| WO2007140383A2 (en) | 2006-05-30 | 2007-12-06 | Neurogen Corporation | Spirocyclic sulfonamides and related compounds |
| BRPI0714764A2 (pt) | 2006-09-29 | 2014-12-30 | Gruenenthal Gmbh | Derivados substituídos de sulfonamida |
| EP2086935A1 (de) * | 2006-10-16 | 2009-08-12 | Grünenthal GmbH | Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren |
-
2009
- 2009-09-11 TW TW098130643A patent/TW201022267A/zh unknown
- 2009-10-22 WO PCT/EP2009/007568 patent/WO2010046109A1/de not_active Ceased
- 2009-10-22 AR ARP090104060A patent/AR073919A1/es not_active Application Discontinuation
- 2009-10-22 CA CA2741349A patent/CA2741349A1/en not_active Abandoned
- 2009-10-22 MX MX2011004211A patent/MX2011004211A/es not_active Application Discontinuation
- 2009-10-22 BR BRPI0920496A patent/BRPI0920496A2/pt not_active IP Right Cessation
- 2009-10-22 PT PT97408603T patent/PT2356101E/pt unknown
- 2009-10-22 HR HRP20130423AT patent/HRP20130423T1/hr unknown
- 2009-10-22 ES ES09740860T patent/ES2409109T3/es active Active
- 2009-10-22 JP JP2011532539A patent/JP2012506396A/ja not_active Withdrawn
- 2009-10-22 PL PL09740860T patent/PL2356101T3/pl unknown
- 2009-10-22 AU AU2009306723A patent/AU2009306723A1/en not_active Abandoned
- 2009-10-22 DK DK09740860.3T patent/DK2356101T3/da active
- 2009-10-22 SI SI200930539T patent/SI2356101T1/sl unknown
- 2009-10-22 EP EP09740860A patent/EP2356101B1/de not_active Not-in-force
- 2009-10-23 US US12/604,691 patent/US8269000B2/en not_active Expired - Fee Related
-
2013
- 2013-04-23 CY CY20131100330T patent/CY1113942T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2356101T3 (pl) | 2013-07-31 |
| US20100173889A1 (en) | 2010-07-08 |
| JP2012506396A (ja) | 2012-03-15 |
| BRPI0920496A2 (pt) | 2019-09-24 |
| US8269000B2 (en) | 2012-09-18 |
| AU2009306723A1 (en) | 2010-04-29 |
| TW201022267A (en) | 2010-06-16 |
| ES2409109T3 (es) | 2013-06-25 |
| CA2741349A1 (en) | 2010-04-29 |
| EP2356101B1 (de) | 2013-02-27 |
| SI2356101T1 (sl) | 2013-04-30 |
| PT2356101E (pt) | 2013-06-03 |
| CY1113942T1 (el) | 2016-07-27 |
| MX2011004211A (es) | 2011-05-24 |
| HRP20130423T1 (en) | 2013-06-30 |
| WO2010046109A1 (de) | 2010-04-29 |
| AR073919A1 (es) | 2010-12-09 |
| EP2356101A1 (de) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1945631T3 (da) | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer | |
| DK2283024T3 (da) | 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer | |
| DK2120932T3 (da) | Indazolderivater som kinasehæmmere til behandling af kræft | |
| BRPI0810086A2 (pt) | inibidores de tirosina quinase de bruton | |
| DK2261223T3 (da) | Pyrimidinderivater anvendt som PI-3-kinasehæmmere | |
| DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
| CY2017012I1 (el) | Αναστολεις κινασης τυροσινης bruton | |
| DK1877232T3 (da) | Fremgangsmåde til behandling af træoverflader | |
| DK1761505T3 (da) | Pyrimidin-urinstof-derivater som kinaseinhibitorer | |
| NO20082514L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
| DK2300443T3 (da) | Triazolderivater, der er anvendelige til behandling af sygdomme | |
| DK3483143T3 (da) | Piperidinonderivater som mdm2-inhibitorer til behandlingen af kræft | |
| IL226474A0 (en) | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine | |
| NO20091423L (no) | Pyrimidinderivater og deres anvendelse som kinaseinhibitorer | |
| DK3216793T3 (da) | Triazinforbindelser som p13-kinase- og mtor-inhibitorer | |
| DK3808749T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme | |
| DK1833799T3 (da) | 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil | |
| DK1926722T3 (da) | Substituerede benzimidazoler som kinaseinhibitorer | |
| BRPI1009112A2 (pt) | inibidores de tirosina quinase de bruton | |
| DK2307042T3 (da) | Modulering af trpv: vps10p-domænereceptorsystem til behandlingen af smerte | |
| DK2658851T3 (da) | Heterocykliske forbindelser, som er egnede til behandling af dyslipidæmi | |
| DK2177224T3 (da) | Forbindelse til forebyggelse og behandling af lidelser, som involverer modulation af RyR-receptorerne | |
| DK2321295T3 (da) | 4-(pyridin-4-yl)-1h-[1,3,5]triazin-2-olderivater som gsk3-beta inhibitorer for til behandling af neurodegenerative sygdomme | |
| DK2220070T3 (da) | 2-benzylpyridazinonderivater som Met-kinaseinhibitorer | |
| CY1113942T1 (el) | Παραγωγα σουλφοναμιδιου πυριμιδινης και τριαζινης σαν αναστολεις υποδοχεα βραδυκινινης β1 (β1r) για τη θεραπεια πονου |